Characterization of palygorskite clay from Piauí, Brazil and its potential use as excipient for solid dosage forms containing anti-tuberculosis drugs

Journal of Thermal Analysis and Calorimetry

Volumn 113, Issue 2, 2013, Pages 551-558

  Dos Santos Soares, Daiane ^a   Fernandes, Caio Santana ^a   Da Costa, Antônio Carlos S ^a   Raffin, Fernanda Nervo ^a   Acchar, Wilson ^a   De Lima E Moura, Túlio F A ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

Author keywords

Anti tuberculosis drugs; Dissolution assay; Excipients; Palygorskite; Thermal analysis

Indexed keywords

ANTI-TUBERCULOSIS DRUGS; EXCIPIENTS; MINERAL COMPOSITION; PALYGORSKITES; PARTICLE SIZE ANALYZERS; PHYSICOCHEMICAL PROPERTY; SOLID DOSAGE FORMS; X RAY FLUORESCENCE;

AGGLOMERATION; BIOCHEMISTRY; DISSOLUTION; HYDRAZINE; PARTICLE SIZE ANALYSIS; QUARTZ; THERMOANALYSIS; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

DRUG DOSAGE;

EID: 84880510872     PISSN: 13886150     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10973-013-3291-0     Document Type: Conference Paper

References (33)

1. Dutra RPS, Varela ML, Gomes UU, Nascimento do RM, Paskocimas CA, Melo PT. Avaliação da Potencialidade de Argilas do Rio Grande do Norte-Brasil. Cerâm Industr. 2006;36(2):42-6.
2. Viseras C, Lopez-Galindo A. Pharmaceutical applications of some spanish clays (sepiolite, palygorskite, bentonite): some preformulations studies. Appl Clay Sci. 1999;14:69-82.
3. Iborra CV, Cultrone G, Cerezo P, Aguzzi C, Baschini MT, Vllés J, Lopez-Galindo A. Characterisation of northern patagonian bentonites for pharmaceutical uses. Appl Clay Sci. 2006;32:272-81.
4. Carretero MI, Pozo M. Clay and non-clay minerals in the pharmaceutical industry, part I: excipients and medical applications. Appl Clay Sci. 2009;46:73-80.
5. Carretero MI, Pozo M. Clay and non-clay minerals in the pharmaceutical and cosmetical industries, part II: active ingredients. Appl Clay Sci. 2010;47:171-81.
6. Jung H, Kim H, Choy YB, Hwang SJ, Choy JH. Laponite-based nanohybrid for enhanced solubility and controlled release of itraconazole. Int J Pharm. 2008;349:283-90.
7. Park JK, Choy YB, Oh JM, Kima JY, Hwanga SJ, Choy JH. Controlled release of donepezil intercalated in smectite clays. Int J Pharm. 2008;359:198-204.
8. Joshi GV, Kevadiya BD, Patel HA, Bajaj HC, Jasra RV. Montmorillonite as a drug delivery system: intercalation and in vitro release of timolol maleate. Int J Pharm. 2009;374:53-7.
9. Cornejo J, Hermosin MC, White JL, Peck GE, Hhem SL. Role of ferric iron in the oxidation of hydrocortisone by sepiolite and palygorskite. Clays Clay Miner. 1983;31(2):109-12.
10. White JL, Hem SL. Pharmaceutical aspects for clay-organic interactions. Ind Eng Chem Prod Res Dev. 1983;22:665-71.
11. Naggar VF. An in vitro study of the interaction between diazepam and some antacids or excipients. Pharmazie. 1981;36:114-7.
12. Dhanaraju MD, Kumaran KS, Baskaran T, Moorthy MS. Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin. Drug Dev Ind Pharm. 1998;24(6):583-7.
13. Panakanti R, Narang AS. Impact of excipient interactions on drug bioavailability from solid dosage forms. Pharm Res. 2012. doi: 10.1007/s11095-012-0767-8.
14. Santos AFO, Basilio ID, de Souza FS, Medeiros AFD, Pinto MF, de Santana DP, et al. Application of thermal analysis in study of binary mixtures with metformin. J Therm Anal Calorim. 2008;93:361-4.
15. Freire F, Aragão CF, Moura TFAL, Raffin FN. Compatibility study between chlorpropamide and excipients in their physical mixtures. J Therm Anal Calorim. 2009;97:355-7.
16. Lavor EP, Freire F, Aragão CF, Moura TFAL, Raffin FN. Application of thermal analysis to the study of anti-tuberculosis drug compatibility: part I. J Therm Anal Calorim. 2011. doi: 10.1007/10973-01101770-8.
17. Pinto MA, de Moura EA, de Souza FS, Macêdo RO. Thermal compatibility studies of nitroimidazoles and excipients. J Therm Anal Calorim. 2010;102:323-9.
18. Frost RL, Ding Z. Controlled rate thermal analysis and differential scanning calorimetry of sepiolites and palygorskites. Thermochim Acta. 2003;397:119-28.
19. World Health Organization. Global tuberculosis control: WHO report 2011. Available at: http://www.who.int/tb/publications/global-report/2011/gtbr11-full. pdf Accessed 03 July 2012.
20. Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-20.
21. Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm. 2001;228:53-67.
22. Pelizza G, Nebuloni M, Ferrari P, Gallo GG. Polymorphism of rifampicin. Farmaco Sci. 1977;32:471-81.
23. Henwood SQ, de Villiers MM, Leibenberg W, Lotter AP. Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev Ind Pharm. 2000;26:403-8.
24. Singh S, Mariappan TT, Sankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor/variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm. 2001;228:5-17.
25. Agrawal S, Ashokraj Y, Bharatam PV, Pillai O, Panchagnula R. Solid state characterization of rifampicin samples and its biopharmaceutic relevance. Eur J Pharm Sci. 2004;22:127-44.
26. Liu H, Chen T, Chang D, Chen D, Qing C, Xie J, Frost RL. The difference of thermal stability between Fe-substituted palygorskite and Al-rich palygorskite. J Therm Anal Calorim. 2012. doi: 10.1007/s10973-012-2363-x.
27. Cheng H, Yang J, Frost RL. Thermogravimetric analysis-mass spectrometry (TG-MS) of selected Chinese palygorskites: implications for structural water. Thermochim Acta. 2011;512:202-7.
28. Freire F, Aragão CF, Moura TFAL, Raffin FN. Thermal studies of isoniazid and mixtures with rifampicin. J Therm Anal Calorim. 2009;97:333-6.
29. Akyuz S, Akyuz T, Akalin E. Adsorption of isoniazid onto sepiolite-palygorskite group of clays: an IR study. Spectrochim Acta Part A. 2010;75:1304-7.
30. Lavor EP, Freire FD, Aragão CF, Raffin FN, Moura TFAL. Application of thermal analysis to the study of anti-tuberculosis drug-excipient compatibility Part 1. J Therm Anal Calorim. 2012;108:207-12.
31. Wang J, Wen H, Desai D. Lubrication in tablet formulations. Eur J Pharm Biopharm. 2010;75:1-15.
32. McGinity JW, Harris MR. Increasing dissolution rates of poorly soluble drugs by adsorption to montmorillonite. Drug Dev Ind Pharm. 1980;6:35-48.
33. Sanganwar GP, Gupta RB. Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. Int J Pharm. 2008;360(1-2):213-8.